Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188546 | 0.91 | CYP1A2 (0.54) | CHRM3CHRM1CYP1A2TDP1HSD17B10 | |
| SCHEMBL25514015 | 0.89 | ALDH1A1 (0.46) | HTTLMNACHRM1KMT2AMEN1 | |
| SCHEMBL4546653 | 0.87 | — | — | |
| SCHEMBL16906761 | 0.86 | HTT (0.50) | HTTLMNACHRM3CHRM1CYP1A2 | |
| SCHEMBL19640023 | 0.84 | HTT (0.49) | HTTLMNACHRM3CHRM1CYP1A2 | |
| SCHEMBL19640106 | 0.84 | HTT (0.49) | HTTLMNACHRM3CHRM1CYP1A2 | |
| SCHEMBL1106510 | 0.82 | CHRNB2 (0.46) | HTTKMT2AMEN1 | |
| SCHEMBL674660 | 0.82 | — | — | |
| SCHEMBL22753493 | 0.82 | CHRNB2 (0.50) | LMNAKMT2APOLBMEN1MAPT | |
| SCHEMBL4546617 | 0.82 | CHRNB2 (0.50) | LMNAKMT2APOLBMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230038589-A1 | Methods and compositions for targeting Tregs using CCR8 inhibitors | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-20230010358-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | PRELUDE THERAPEUTICS, INCORPORATED | 2023-01-12 | — | — | US | disclosed |
| WO-2022000443-A1 | METHODS AND COMPOSITIONS FOR TARGETING TREGS USING CCR8 INHIBITORS | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2022-01-06 | — | — | WO | disclosed |
| US-9988391-B2 | TBK/IKK inhibitor compounds and uses thereof | MERCK PATENT GMBH (DE) | 2018-06-05 | — | — | US | disclosed |
| US-9988391-B2 | TBK/IKK inhibitor compounds and uses thereof | MERCK PATENT GMBH (DE) | 2018-06-05 | — | — | US | disclosed |
| US-9834521-B2 | Choline kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834521-B2 | Choline kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20100197662-A1 | HETEROCYCLIC COMPOUND HAVING TYPE I 11 BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20090131491-A1 | ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I | SHIONOGI & CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20080249081-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN AND SCREENING METHODS THEREFOR | ACADIA PHARMACEUTICALS INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080249081-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN AND SCREENING METHODS THEREFOR | ACADIA PHARMACEUTICALS INC. | 2008-10-09 | — | — | US | disclosed |
| US-7354919-B2 | Isoxazole compositions useful as inhibitors of ERK | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-08 | — | — | US | disclosed |
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | CAO JINGRONG | 2007-11-15 | — | — | US | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| US-7253187-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-07 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | CCR8, CCR1, CCR3 | HTT 4727/4885LMNA 4214/4885CHRM3 3146/4885 |
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAPKAPK2 | HTT 4746/4885LMNA 4102/4885CHRM3 3214/4885 |
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | HTT 3149/4885LMNA 3763/4885CHRM3 2788/4885 |
| US-20100197662-A1 | HETEROCYCLIC COMPOUND HAVING TYPE I 11 BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | HSD11B1, HSD3B1, HSD11B2 | HTT 3987/4885LMNA 2799/4885CHRM3 2136/4885 |
| US-20090131491-A1 | ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I | HSD3B1, NR5A1, HSD11B1 | HTT 4671/4885LMNA 3345/4885CHRM3 1450/4885 |
| US-20070197628-A1 | Cannabinoid receptor modulators | CNR1, CNR2, GPR18 | HTT 2641/4885LMNA 3635/4885CHRM3 361/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | HTT 4445/4885LMNA 4386/4885CHRM3 252/4885 |
| US-20080249081-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN AND SCREENING METHODS THEREFOR | MRGPRX2, MRGPRX4, MRGPRX1 | HTT 4557/4885LMNA 3654/4885CHRM3 2377/4885 |
| US-20230038589-A1 | Methods and compositions for targeting Tregs using CCR8 inhibitors | CCR8, CCR1, CCR3 | HTT 4727/4885LMNA 4214/4885CHRM3 3146/4885 |
| US-20230010358-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | MCL1, BCL2A1, BCL2L1 | HTT 3250/4885LMNA 949/4885CHRM3 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.